Regional Academic Health Center-Edinburg (E-RAHC), Medical Research Division, 1214 W. Schunior St., Edinburg, TX 78541, United States.
Neurochem Int. 2013 Jan;62(1):31-42. doi: 10.1016/j.neuint.2012.10.014. Epub 2012 Nov 7.
Inhibition of proteasome activity and the resulting protein accumulation are now known to be important events in the development of many neurological disorders, including Alzheimer's and Parkinson's diseases. Abnormal or over expressed proteins cause endoplasmic reticulum and oxidative stress leading to cell death, thus, normal proteasome function is critical for their removal. We have shown previously, with cultured SH-SY5Y neuroblastoma cells, that proteasome inhibition by the drug epoxomicin results in accumulation of ubiquitinated proteins. This causes obligatory loading of the mitochondria with calcium (Ca(2+)), resulting in mitochondrial damage and cytochrome c release, followed by programmed cell death (PCD). In the present study, we demonstrate that all-trans-retinoic acid (RA) pretreatment of SH-SY5Y cells protects them from PCD death after subsequent epoxomicin treatment which causes proteasome inhibition. Even though ubiquitinated protein aggregates are present, there is no evidence to suggest that autophagy is involved. We conclude that protection by RA is likely by mechanisms that interfere with cell stress-PCD pathway that otherwise would result from protein accumulation after proteasome inhibition. In addition, although RA activates both the AKT and ERK phosphorylation signaling pathways, only pretreatment with LY294002, an inhibitor of PI3-kinase in the AKT pathway, removed the protective effect of RA from the cells. This finding implies that RA activation of the AKT signaling cascade takes precedence over its activation of ERK1/2 phosphorylation, and that this selective effect of RA is key to its protection of epoxomicin-treated cells. Taken together, these findings suggest that RA treatment of cultured neuroblastoma cells sets up conditions under which proteasome inhibition, and the resultant accumulation of ubiquitinated proteins, loses its ability to kill the cells and may likely play a therapeutic role in neurodegenerative diseases.
蛋白酶体活性的抑制以及由此导致的蛋白质积累,现在已知是许多神经退行性疾病(包括阿尔茨海默病和帕金森病)发展过程中的重要事件。异常或过度表达的蛋白质会导致内质网和氧化应激,从而导致细胞死亡,因此,正常的蛋白酶体功能对于它们的清除至关重要。我们之前已经在培养的 SH-SY5Y 神经母细胞瘤细胞中表明,药物环氧酶素对蛋白酶体的抑制会导致泛素化蛋白的积累。这会迫使线粒体强制性加载钙(Ca(2+)),导致线粒体损伤和细胞色素 c 释放,随后是程序性细胞死亡(PCD)。在本研究中,我们证明了全反式视黄酸(RA)预处理 SH-SY5Y 细胞可防止随后的环氧酶素处理导致蛋白酶体抑制后发生 PCD 死亡。尽管存在泛素化蛋白聚集体,但没有证据表明自噬参与其中。我们得出的结论是,RA 的保护作用可能是通过干扰细胞应激-PCD 途径的机制实现的,否则蛋白酶体抑制后蛋白质积累会导致这种途径。此外,尽管 RA 激活 AKT 和 ERK 磷酸化信号通路,但只有 PI3-激酶抑制剂 LY294002 预处理才能消除 RA 对细胞的保护作用。这一发现表明,RA 对 AKT 信号级联的激活优先于其对 ERK1/2 磷酸化的激活,而 RA 的这种选择性作用是其保护环氧酶素处理细胞的关键。总之,这些发现表明 RA 处理培养的神经母细胞瘤细胞会建立条件,在这些条件下,蛋白酶体抑制和由此产生的泛素化蛋白积累会丧失杀死细胞的能力,并且可能在神经退行性疾病中发挥治疗作用。